KYMR Kymera Therapeutics

Kymera Therapeutics to Present at the Stifel 2020 Virtual Healthcare Conference

Kymera Therapeutics to Present at the Stifel 2020 Virtual Healthcare Conference

WATERTOWN, Mass., Nov. 11, 2020 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system, today announced Nello Mainolfi, Co-Founder, President and CEO of Kymera Therapeutics, will present at the Stifel 2020 Virtual Healthcare Conference at 8:00 a.m. ET on Tuesday, November 17, 2020.

A live webcast of the presentation can be accessed under "Events and Presentations" in the Investors section of the Company's website at An archived webcast recording of the presentation will be available on the website for approximately 90 days.

About Kymera Therapeutics

Kymera Therapeutics is a biopharmaceutical company focused on a transformative new approach to address previously intractable disease targets. Kymera is advancing the field of targeted protein degradation, accessing the body’s innate protein recycling machinery to degrade dysregulated, disease-causing proteins. Kymera’s Pegasus targeted protein degradation platform harnesses the body’s natural protein recycling machinery to degrade disease-causing proteins, with a focus on un-drugged nodes in validated pathways currently inaccessible with conventional therapeutics. Kymera is accelerating drug discovery with an unmatched ability to target and degrade the most intractable of proteins, and advance new treatment options for patients. Kymera’s initial programs target IRAK4, IRAKIMiD and STAT3 within the IL-1R/TLR or JAK/STAT pathways, providing the opportunity to treat a broad range of immune-inflammatory diseases, hematologic malignancies and solid tumors. For more information, visit

Contact:



Bruce Jacobs

Chief Financial Officer

+1 857.285.5300

Christopher F. Brinzey

Westwicke, an ICR Company for Kymera Therapeutics



+1 339.970.2843

Lissette L. Steele

Verge Scientific Communications for Kymera Therapeutics



+1 202.930.4762

EN
11/11/2020

Underlying

KYMRKymera Therapeutics

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Kymera Therapeutics

 PRESS RELEASE
Free
KYMR Kymera Therapeu...

Kymera Therapeutics Announces Fourth Quarter and Full Year 2025 Financ...

Kymera Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update KT-621 (STAT6) BROADEN2 Phase 2b trial in atopic dermatitis (AD) ongoing, with data expected by mid-2027 KT-621 BREADTH Phase 2b trial in asthma ongoing, with data expected in late-2027 Initiated dosing in KT-579 (IRF5) Phase 1 healthy volunteer trial with data expected in 2H26 Dr. Neil Graham, experienced biopharma leader, appointed Chief Development Officer Well-capitalized with $1.6 billion in cash as of December 31, 2025, and runway into 2029 Company to hold video con...

February 26, 2026 1 EN
 PRESS RELEASE
Free
KYMR Kymera Therapeu...

Kymera Therapeutics to Participate in Upcoming March Investor Conferen...

Kymera Therapeutics to Participate in Upcoming March Investor Conferences WATERTOWN, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced that the Company will participate in fireside chats at the following upcoming investor events:  TD Cowen 46th Annual Healthcare Conference in Boston, MA on March 3 at 9:10 a.m. ET;Leerink Partners Global Healthcare Conference in Miami, FL on March 10 at 11:20 a.m. ET; andBarclays 28th Annual Global ...

February 24, 2026 1 EN
 PRESS RELEASE
Free
KYMR Kymera Therapeu...

Kymera Therapeutics to Report Fourth Quarter and Full Year 2025 Financ...

Kymera Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026 WATERTOWN, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, will report fourth quarter and full year 2025 financial results on February 26, 2026. The Company will host a video conference call and webcast at 8:30 a.m. ET that day. To join the video call or view the livestreamed webcast, please register via , or visit “” in the Investors section o...

February 19, 2026 1 EN
 PRESS RELEASE
Free
KYMR Kymera Therapeu...

Kymera Therapeutics to Participate in Upcoming February Investor Confe...

Kymera Therapeutics to Participate in Upcoming February Investor Conferences WATERTOWN, Mass., Feb. 04, 2026 (GLOBE NEWSWIRE) -- (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced that the Company will participate in fireside chats at the following upcoming investor events:  Guggenheim Emerging Outlook: Biotech Summit 2026 in New York, NY on February 11 at 9:00 a.m. ET; andOppenheimer Virtual 36th Annual Healthcare Life Sciences Conference on February 26 at 2:00 p.m. ET. ...

February 4, 2026 1 EN
 PRESS RELEASE
Free
KYMR Kymera Therapeu...

Kymera Therapeutics Announces First Patient Dosed in BREADTH Phase 2b ...

Kymera Therapeutics Announces First Patient Dosed in BREADTH Phase 2b Asthma Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader Data from the BREADTH Phase 2b asthma trial is expected to be reported in late-2027 Data from the ongoing parallel BROADEN2 Phase 2b atopic dermatitis trial is expected to be reported by mid-2027 WATERTOWN, Mass., Jan. 29, 2026 (GLOBE NEWSWIRE) -- (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced that it recently initiated dosing i...

January 29, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch